Wall Street analysts forecast that Kamada Ltd. (NASDAQ:KMDA) will announce $0.01 earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Kamada’s earnings. The highest EPS estimate is $0.02 and the lowest is ($0.01). Kamada reported earnings of ($0.03) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 133.3%. The firm is expected to announce its next quarterly earnings report on Thursday, November 9th.

On average, analysts expect that Kamada will report full year earnings of $0.06 per share for the current fiscal year, with EPS estimates ranging from $0.03 to $0.09. For the next fiscal year, analysts anticipate that the company will report earnings of $0.20 per share, with EPS estimates ranging from $0.19 to $0.21. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Kamada.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.01. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The company had revenue of $32.55 million for the quarter, compared to the consensus estimate of $33.30 million. During the same quarter last year, the business posted ($0.04) EPS. Kamada’s revenue for the quarter was up 70.7% on a year-over-year basis.

Several analysts have issued reports on KMDA shares. ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Jefferies Group LLC restated a “buy” rating and set a $7.00 price target (down from $9.00) on shares of Kamada in a research report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Kamada from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th. Finally, TheStreet lowered shares of Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $8.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Edmond DE Rothschild Holding S.A. boosted its holdings in shares of Kamada by 10.5% during the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,000 shares during the period. Navellier & Associates Inc purchased a new stake in shares of Kamada during the second quarter worth about $303,000. Renaissance Technologies LLC boosted its holdings in shares of Kamada by 16.7% during the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after purchasing an additional 37,800 shares during the period. Nexthera Capital LP purchased a new stake in shares of Kamada during the second quarter worth about $1,805,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares during the period. Institutional investors and hedge funds own 7.29% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “$0.01 EPS Expected for Kamada Ltd. (KMDA) This Quarter” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/10/0-01-eps-expected-for-kamada-ltd-kmda-this-quarter.html.

Kamada (NASDAQ:KMDA) remained flat at $4.85 during midday trading on Tuesday. 26,428 shares of the company’s stock traded hands. The company’s 50 day moving average is $4.61 and its 200 day moving average is $5.97. The firm’s market cap is $181.39 million. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.